Certain Restricted Stock Unit of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
How this was made
The 30-second read
Why it matters
The lock‑up does not affect the company's pipeline or financial outlook but may temporarily limit share supply.
Market read
A routine corporate action with limited trading impact; primarily of interest to current shareholders and insiders.
What to watch
Potential future dilution from upcoming equity grants is not addressed.
Background
Amylyx is a clinical‑stage biotech with several investigational therapies; the RSU lock‑up is part of its compensation framework.
Market effects
None significant for the biotech sector.
Limited to U.S. investors holding Amylyx shares.
Minimal
Counterpoint
Investors may view the lock‑up as a signal of confidence by insiders, but the restriction is short and standard.
Key entities
- CompanyAmylyx Pharmaceuticals, Inc.
Clinical‑stage biotech issuing the RSU lock‑up.
- Financial AdvisorLeerink Partners LLC
One of the parties required to approve any share disposals during the lock‑up.
